@article{TLCR31585,
author = {Katsuhiro Masago and Yoshitsugu Horio and Shiro Fujita and Yasushi Yatabe},
title = {Minimal residual disease after radical surgery in EGFR-mutant non-small cell lung cancer},
journal = {Translational Lung Cancer Research},
volume = {8},
number = {Suppl 4},
year = {2019},
keywords = {},
abstract = {Xu et al. performed a post-hoc analysis of a randomized phase III trial (ADJUVANT/CTONG1104) of adjuvant gefitinib therapy in the treatment of Chinese patients who had undergone complete resection for EGFR-mutant stage II-IIIA non-small cell lung cancer (NSCLC) to evaluate patterns of spatial-temporal treatment-failure (1,2). Two hundred twenty-two patients were randomized 1:1 to receive gefitinib or vinorelbine plus cisplatin (VP). Among them, 106 patients received gefitinib treatment, and 87 patients who received VP completed 4 cycles of chemotherapy. One hundred twenty-four patients experienced disease progression during a median follow-up period of 36.5 months.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/31585}
}